The
integrin lymphocyte function-associated antigen-1 (LFA-1) (alphaLbeta2; CD11a/CD18) plays an important role in leukocyte migration and T cell activation.
LFA-1 is inhibited by the
cholesterol-lowering
drug lovastatin, which binds to an allosteric site of the alphaL I domain termed the
lovastatin site (L-site). Here we report for the first time the x-ray structures of the
LFA-1 I domain complexed with derivatives of
lovastatin optimized for
LFA-1 inhibition. This analysis identified two new subpockets within the L-site occupied by chemical groups of the
statin derivatives but not by
lovastatin itself. Occupancy of these L-site subpockets led to distinct conformational changes in
LFA-1, which were detectable by an
epitope-monitoring assay. We utilized this assay to demonstrate improved
LFA-1 inhibition in human blood in vitro and in blood samples from treated animals ex vivo. Moreover, we demonstrate that the novel
lovastatin-derived
LFA-1 inhibitor
LFA878 exhibits potent anti-inflammatory effects in
carrageenan-induced rat paw
edema. In summary, the findings reported here extend the understanding of
LFA-1 inhibition at the molecular level, allow for the identification and design of
LFA-1 inhibitors of further enhanced potency, and support the expectation that
LFA-1 inhibitors binding to the L-site will be of therapeutic value in treating inflammatory diseases.